Canada’s Drug Agency (CDA) has launched a new funding opportunity for rare disease registries to carry out improvement initiatives that strengthen the availability and quality of their real-world data. This marks the third funding opportunity of this kind, building on the strong interest and positive response to the 2 previous open calls delivered in 2024 and 2025.
If you are interested in learning more, be sure to check out the 2026–2027 Rare Disease Registry Request for Proposals (RFP) listed at the bottom of this page and on CDA’s website.
With support from the Government of Canada under the National Strategy for Drugs for Rare Diseases, we are committed to investing in and bolstering rare disease registries to help improve the evidence landscape across Canada and support decision-makers to expand access to safe and effective therapies for people with rare diseases.
All inquiries and submissions by email:
Key Dates of Interest
- Funding launch: April 7, 2026
- Deadline to submit inquiries about proposals: May 5, 2026
- Submission deadline for detailed proposals (Send to contact email): May 14, 2026
- Notification of contract awardees: Mid-June 2026
Refer to the RFP for a complete timeline of key dates.